# Optimal Anti-Thrombotic Management Following Percutaneous Left Atrial Appendage Occlusion

Study · id `cardio:ct-nct07840365` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07840365](<https://clinicaltrials.gov/study/NCT07840365>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07840365

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 234 participants.

## Technical summary

Registry record NCT07840365. Randomized; no masking; primary purpose prevention. Start 2026-09-01 (actual); primary completion 2028-12-15 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 234 participants (planned count; ClinicalTrials.gov record NCT07840365, source copy `cardio:ctgov-nct07840365-2026-10-05`, retrieved 2026-10-26)
- Started: 2026-09-01 (actual) (ClinicalTrials.gov record NCT07840365, source copy `cardio:ctgov-nct07840365-2026-10-05`, retrieved 2026-10-26)
- Primary completion: 2028-12-15 (anticipated) (ClinicalTrials.gov record NCT07840365, source copy `cardio:ctgov-nct07840365-2026-10-05`, retrieved 2026-10-26)
- Completion: 2029-09-30 (anticipated) (ClinicalTrials.gov record NCT07840365, source copy `cardio:ctgov-nct07840365-2026-10-05`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT07840365, source copy `cardio:ctgov-nct07840365-2026-10-05`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07840365-2026-10-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: Optimal Anti-Thrombotic Management Following Percutaneous Left Atrial Appendage Occlusion
- Acronym: INTEGRAL
- Condition: Atrial Fibrillation (AF)
- Intervention (Drug): Half-Dose of novel OAC
- Intervention (Drug): Low-dose ASA
- Lead sponsor: Texas Cardiac Arrhythmia Research Foundation
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Texas Cardiac Arrhythmia Research Foundation (`cardio:org-texas-cardiac-arrhythmia-research-foundation`)

## Provenance

Content hash: 460c1402935fb22d94b6a59dd937848de29db1df32f72faf49ae30c3b57b88d5
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
